Inhibrx Biosciences, Inc. (INBX) Stock
7 of the hedge funds AlphaScala tracks reported INBX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Viking Global Investors's at $106.49M. Company insiders reported 20 open-market buys and 5 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own INBX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Viking Global Investors Andreas Halvorsen | 1.12M | $106.49M | -22% |
| Millennium Management Israel Englander | 147K | $13.95M | -55% |
| Renaissance Technologies Jim Simons (founder) | 62K | $5.89M | +24% |
| Hussman Investment Trust John Hussman | 32K | $2.98M | NEW |
| Point72 Steve Cohen | 26K | $2.46M | NEW |
| D.E. Shaw David Shaw | 22K | $2.12M | -71% |
| Marshall Wace | 9K | $833.8K | -58% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Inhibrx Biosciences, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 14, 26 | Lappe Mark | Chief Executive Officer | BUY | 2.5K | $208K |
| Oct 14, 26 | Lappe Mark | Chief Executive Officer | BUY | 2.5K | $210K |
| Oct 14, 26 | Lappe Mark | Chief Executive Officer | BUY | 100 | $9K |
| Oct 14, 26 | Lappe Mark | Chief Executive Officer | BUY | 2.4K | $206K |
| Oct 14, 26 | Lappe Mark | Chief Executive Officer | BUY | 2.5K | $208K |
| Oct 14, 26 | Lappe Mark | Chief Executive Officer | BUY | 100 | $9K |
| Sep 28, 26 | Lappe Mark | Chief Executive Officer | BUY | 1.5K | $148K |
| Sep 28, 26 | Lappe Mark | Chief Executive Officer | BUY | 3.0K | $305K |
| Sep 25, 26 | Lappe Mark | Chief Executive Officer | BUY | 3.3K | $329K |
| Sep 25, 26 | Lappe Mark | Chief Executive Officer | BUY | 2.2K | $217K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →INBX price chart
Powered by TradingViewWhat does Inhibrx Biosciences, Inc. do?
Inhibrx Inc. is a biotechnology company that focuses on developing monoclonal antibodies used for treating a range of life-threatening diseases. The company’s primary objective is to innovate targeted therapies that can address significant unmet medical needs in the areas of oncology, rare diseases, and autoimmune conditions. Notably, Inhibrx leverages its proprietary single-domain antibody technology platform to engineer highly differentiated biological therapies. By concentrating on precision medicine, the firm's approach aims to deliver more effective solutions with the potential for enhanced patient outcomes as compared to traditional treatments. Operating in the burgeoning biotechnology sector, Inhibrx contributes to the advancement of medical research and the development of targeted therapies. The company's role in the financial market encompasses that of a high-growth potential entity, attracting interest from investors focused on cutting-edge healthcare innovations and the broader biotechnology industry developments.